



Antibacterial Therapy in Adults with COVID-19

Guest Editors:

Prof. Dr. Sabine Danielle Allard

Department of Internal Medicine
and Infectious Diseases, Vrije
Universiteit Brussel (VUB),
Universitair Ziekenhuis Brussel,
1090 Brussels, Belgium

Dr. Johan Van Laethem

Department of Internal Medicine
and Infectious Diseases, Vrije
Universiteit Brussel (VUB),
Universitair Ziekenhuis Brussel,
1090 Brussels, Belgium

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Since the emergence of the Coronavirus-19 infectious disease (COVID-19) pandemic, a rising number of reports have underlined the risk of increasing antimicrobial resistance due to antibiotic overuse in COVID-19 patients. In addition, many physicians and pharmacists involved in antimicrobial stewardship have had to shift their activities to the containment of the COVID-19 crisis. In contrast to this observed overconsumption of antibiotics, very few bacterial superinfections have been documented in COVID-19 patients, especially in patients admitted outside the intensive care unit and in the first days of admission. However, identification of bacterial co-/superinfections in COVID-19 patients is difficult, as inflammatory and radiological markers of bacterial infection lack specificity in this setting. Furthermore, studies regarding the effect of immune suppression, including the use of corticosteroids and anti-interleukins, and the effect of potential immunomodulatory properties of certain antibiotics on the occurrence of bacterial co-/superinfection are needed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)